Effects of levofloxacin, moxifloxacin and prulifloxacin on murine gut colonization by Candida albicans

References

• Neofytos D, Horn D, Anaissie E, . Epidemiology and outcome of invasive fungal infection in adult hemopoietic stem cell transplant recipients; analysis of multicenter prospective antifungal therapy (PATH) alliance registry. Clin Infect Dis 2009; 48: 265–273.
   PubMed Web of Science ®Google Scholar
• Rüping MJ, Vehreschild JJ, Cornely OA. Patients at risk of invasive fungal infections: when and how to treat. Drugs 2008; 68: 1941–1962.
   PubMed Web of Science ®Google Scholar
• Zilberberg MD, Shorr AF. Fungal infections in the ICU. Infect Dis Clin North Am 2009; 23: 625–642.
   PubMed Web of Science ®Google Scholar
• Maertens J, Vrebos M, Boogaerts M. Assessing risk factors for systemic fungal infections. Eur J Cancer Care 2001; 10: 56–62.
   PubMed Web of Science ®Google Scholar
• Wisplinghoff H, Bischoff T, Tallent SM, . Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004; 39: 309–317.
   PubMed Web of Science ®Google Scholar
• Marchetti O, Bille J, Fluckiger U, . Epidemiology of candidemia in Swiss hospitals: secular trends, 1991–2000. Clin Infect Dis 2004; 38: 311–320.
   PubMed Web of Science ®Google Scholar
• Falagas ME, Apostolou KE, Pappas VD. Attributable mortality of candidemia; a systemic review of matched cohort and case-control studies. Eur J Clin Microbiol Infect Dis 2006; 25: 419–425.
   PubMed Web of Science ®Google Scholar
• McNeil MM, Nash SL, Hajjeh RA, . Trends in mortality due to invasive mycotic diseases in the United States, 1980–1997. Clin Infect Dis 2001; 33: 641–647.
   PubMed Web of Science ®Google Scholar
• Kennedy MJ, Volz PA, Edward CA, Yancey RJ. Mechanisms of association of Candida albicans with intestinal mucosa. J Med Microbiol 1987; 24: 333–341.
   PubMed Web of Science ®Google Scholar
• Kennedy MJ, Volz PA. Effect of various antibiotics on gastrointestinal colonization and dissemination by Candida albicans. Sabouraudia 1985; 23: 265–273.
   PubMedGoogle Scholar
• Krause W, Matheis H, Wulf K. Fungemia and funguria after oral administration of Candida albicans. Lancet 1969; 1: 598–599.
   PubMed Web of Science ®Google Scholar
• Samonis G, Anaissie EJ, Rosenbaum B, Bodey GP. A model of sustained gastrointestinal colonization by Candida albicans in healthy adult mice. Infect Immun 1990; 58: 1514–1517.
   PubMed Web of Science ®Google Scholar
• Mavromanolakis E, Maraki S, Cranidis A, . The impact of norfloxacin, ciprofloxacin and ofloxacin on human gut colonization by Candida albicans. Scand J Infect Dis 2001; 33: 477–478.
   PubMedGoogle Scholar
• Samonis G, Mantadakis E, Barbounakis E, . Effects of tigecycline and daptomycin on murine gut colonization by Candida albicans.Mycoses 2008; 51: 324–327.
   PubMedGoogle Scholar
• Freireich EJ, Gehan EA, Rall DP, Schmidt LH, Skipper HE. Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man. Cancer Chemother Rep 1966; 50: 219–244.
   PubMedGoogle Scholar
• Sullivan A, Edlund C, Nord CE. Effect of antimicrobial agents on the ecological balance of human microflora. Lancet Infect Dis 2001; 1: 101–114.
   PubMedGoogle Scholar
• Samonis G, Gikas A, Anaissie EJ, . Prospective evaluation of effects of broad-spectrum antibiotics on gastrointestinal yeast colonization of humans. Antimicrob Agents Chemother 1993; 37: 51–53.
   PubMed Web of Science ®Google Scholar
• Hooper D. Quinolones. Mandell GL, Bennet JE, Dolin R. Principles and Practice of Infectious Diseases, 6th. New York: Churchill Livingstone, 2005: 451–473.
   Google Scholar
• Edlund C, Nord CE. Effect of quinolones on intestinal ecology. Drugs 58 (Suppl. 2): 65–70.
   PubMedGoogle Scholar
• Edlund C, Lindqvist l, Nord CE. Norfloxacin binds to human fecal material. Antimicrob Agents Chemother 1988; 32: 1869–1874.
   PubMed Web of Science ®Google Scholar
• Edlund C, Beyer G, Hiemer-Bau M, . Comparative effects of moxifloxacin and clarithromycin on the normal intestinal microflora. Scand J Infect Dis 2000; 32: 81–85.
   PubMedGoogle Scholar
• Samonis G, Kofteridis DP, Maraki S, . Levofloxacin and moxifloxacin increase human gut colonization by Candida species. Antimicrob Agents Chemother 2005; 49: 5189.
   PubMed Web of Science ®Google Scholar
• Ianniello F, Noviello S, Leone S, . Changes in intestinal microflora following levofloxacin administration in laboratory animals. Infez Med 2005; 13: 168–174.
   PubMedGoogle Scholar
• Edlund C, Sjöstedt S, Nord CE. Comparative effects of levofloxacin and ofloxacin on the normal oral and intestinal microflora. Scand J Infect Dis 1997; 29: 383–386.
   PubMed Web of Science ®Google Scholar
• Inagaki Y, Nakaya R. The effect of levofloxacin, an optically-active isomer of ofloxacin, on fecal microflora in human volunteers. Jpn J Antibiot 1992; 45: 241–252.
   PubMedGoogle Scholar
• Noviello S, Ianniello F, Leone S, Esposito S. In vitro activity of prulifloxacin, levofloxacin and ciprofloxacin against urinary pathogens. Inf Med 2006; 14: 24–28.
   Google Scholar
• Montanari MP, Mingoia M, Varaldo P. In vitro antibacterial activities of AF 3013, the active metabolite of prulifloxacin, against nosocomial and community Italian isolates. Antimicrob Agents Chemother 2001; 45: 3616–3622.
   PubMed Web of Science ®Google Scholar
• Prats G, Roig C, Miró E, Navarro F, Mirelis B. In vitro activity of the active metabolite of prulifloxacin (AF 3013) compared with six other fluoroquinolones. Eur J Clin Microbiol Infect Dis 2002; 21: 328–334.
   PubMed Web of Science ®Google Scholar
• Picollo R, Brion N, Gualano V, . Pharmacokinetics and tolerability of prulifloxacin after single oral administration. Arzneimittelforschung 2003; 53: 201–205.
   PubMed Web of Science ®Google Scholar
• Tomii Y, Ozaki M, Matsuda M, . Therapeutic effect of the quinolone prodrug prulifloxacin against experimental urinary tract infections in mice. Arzneimittelforschung 1996; 46: 1169–1173.
   PubMedGoogle Scholar